Empowered Patient Podcast

Dr. William Frey, Senior Research Director, Center for Memory and Aging, HealthPartners Neuroscience Center shares his insights about delivering therapeutic agents to the brain by-passing the blood-brain barrier. Based on an unusual dream he had in 1989, Bill has been on the path to discover and patent a noninvasive intranasal method of delivering drugs to the brain to treat Alzheimer's and other brain disorders. Bill also warns that we should be looking at how COVID-19 is reaching the brain and any long-term impact the virus might have.

Center for Memory and Aging

Listen to the podcast here

Dr. William Frey, Senior Research Director, Center for Memory and Aging, HealthPartners Neuroscience Center shares his insights about delivering therapeutic agents to the brain by-passing the blood-brain barrier. Based on an unusual dream he had in 1989, Bill has been on the path to discover and patent a noninvasive intranasal method of delivering drugs to the brain to treat Alzheimer's and other brain disorders. Bill also warns that we should be looking at how COVID-19 is reaching the brain and any long-term impact the virus might have.

Center for Memory and Aging

Download the transcript here

Sanjeev Luther, President and CEO, Rafael Pharmaceuticals discusses how tumor cell metabolism has recently attracted substantial attention as an area for the development of drugs to treat cancer. Rafael is a company leading the field of cancer metabolism with their drug CPI-613 (devimistat) currently being tested in Phase 1, 2, and 3 clinical trials for patients with rare cancers, including pancreatic cancer, acute myeloid leukemia (AML) and Burkitt's lymphoma.

@RafaelPharma

#RafaelPharma #cancermetabolism #pancreaticcancer #CPI613

RafaelPharma.com

Listen to the podcast here

Sanjeev Luther, President and CEO, Rafael Pharmaceuticals discusses how tumor cell metabolism has recently attracted substantial attention as an area for the development of drugs to treat cancer. Rafael is a company leading the field of cancer metabolism with their drug CPI-613 (devimistat) currently being tested in Phase 1, 2, and 3 clinical trials for patients with rare cancers, including pancreatic cancer, acute myeloid leukemia (AML) and Burkitt's lymphoma.

@RafaelPharma

#RafaelPharma #cancermetabolism #pancreaticcancer #CPI613

RafaelPharma.com

Download the transcript here

David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma. A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few options to treat Ewing's sarcoma, a rare orphan pediatric disease, Salarius is testing a new treatment that can provide hope to patients by inhibiting the LSD1 enzyme and effectively addressing the dysregulation.

@salariuspharma

#ewingsarcoma #ewingssarcoma #rarediseases

Salariuspharma.com

Listen to the podcast here

David Arthur, CEO, Salarius Pharmaceuticals explains the role of our epigenome and what happens when someone is suffering from an epigenetic illness such as Ewing's sarcoma. A whole series of cancers can trace their cause back to the body misreading genes and that leads to dysregulation of genetic expression. With few options to treat Ewing's sarcoma, a rare orphan pediatric disease, Salarius is testing a new treatment that can provide hope to patients by inhibiting the LSD1 enzyme and effectively addressing the dysregulation.

@salariuspharma

#ewingsarcoma #ewingssarcoma #rarediseases

Salariuspharma.com

Download the transcript here

Dr. Andrea Madrigrano is a general surgeon with an expertise in breast cancer at Rush University Medical Center in Chicago. She shares her concern about the high rate of re-excision, the need for a second operation, after a lumpectomy to save the breast with early-stage cancer. Dr. Madrigrano discusses how the Kubtec Mozart 3D tomosynthesis unit allows surgeons to make more informed decisions in near real time cutting re-excision rates in half.

#breastcancer #cancer #KubtecMozart #lumpectomy

@madrigrano_am

Listen to the podcast here

Dr. Andrea Madrigrano is a general surgeon with an expertise in breast cancer at Rush University Medical Center in Chicago. She shares her concern about the high rate of re-excision, the need for a second operation, after a lumpectomy to save the breast with early-stage cancer. Dr. Madrigrano discusses how the Kubtec Mozart 3D tomosynthesis unit allows surgeons to make more informed decisions in near real time cutting re-excision rates in half.

#breastcancer #cancer #KubtecMozart #lumpectomy

@madrigrano_am

Download the transcript here

Tim Moran, CEO, Motus GI talks about their focus on endoscopy solutions that improve clinical outcomes for patients facing a critical colonoscopy while in the hospital. The Pure-Vu system developed by Motus GI is a disposable sleeve that fits on the top of their reusable scope to allow irrigation and suction evacuation. This enhancement can save time by eliminating delays in conducting the colonoscopy as well as reducing costs and need for additional time in the hospital.

@Motus_GI

#colonoscopy

MotusGI.com

Listen to the podcast here

Tim Moran, CEO, Motus GI talks about their focus on endoscopy solutions that improve clinical outcomes for patients facing a critical colonoscopy while in the hospital. The Pure-Vu system developed by Motus GI is a disposable sleeve that fits on the top of their reusable scope to allow irrigation and suction evacuation. This enhancement can save time by eliminating delays in conducting the colonoscopy as well as reducing costs and need for additional time in the hospital.

@Motus_GI

#colonoscopy

MotusGI.com

Download the transcript here